Abstract:Purpose: In this study, we designed a new linear 6-Hydrazinonicotinamide (HYNIC)-conjugated peptide (HYNIC-KRWrNM) (M-6) and labeled with technetium-99m for gamma imaging of glioblastoma as a αvβ3-positive tumor. We evaluated tumor targeting ability of this radio-peptide and compared with previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides. Procedures: One new linear peptide (HYNIC-KRWrNM) (M-6) was designed and labeled with technetium-99m in the presence of 2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl] amino] acetic acid (Tricine)/Ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligand system. Then, this 99mTc-labeled peptide ([99mTc]Tc-M-7) was evaluated for in vitro stability in saline and serum, specific binding assay, internalization, and binding affinity (Kd). In addition, we performed biodistribution study and planar imaging on nude mice bearing U87-MG xenograft as a αvβ3-positive tumor. Results: The radiochemical yield of [99mTc]Tc-M-7 was obtained ˃95%. This 99mTc-labeled peptide remained stable and intact in saline solution after 24 h incubation. In addition, metabolic stability of this 99mTc-labeled peptide was obtained ˃60% after 4 h incubation in serum. The Kd value for [99mTc]Tc-M-7 was obtained 5.2 ± 1.0 nM. Based on biodistribution results in nude mice bearing U87-MG xenograft, tumor/muscle activity ratio was 6.22 and decreased to 1.89 in blocking group at the same time point (4 h p.i.). The blocking experiment results also indicated that tumor uptake and kidney uptake were αvβ3-mediated. In comparison with previous HYNIC-conjugated RGD analogue peptides, kidneys had the highest uptake of this 99mTc-labeled peptide (52.29 ± 11.48 at 1.5 h p.i. and 27.04 ± 0.66%ID/g at 4 h p.i.). Finally, similar to previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides, [99mTc]Tc-M-7 showed acceptable tumor uptake after 4 h post-injection (based on ROI technique, target-to-background activity ratio = 3.80). Conclusions: This small linear 99mTc-labeled peptide, with high affinity to αvβ3 integrin, desirable water solubility, and cost efficient, demonstrates a potent tumor targeting ability as well as previous HYNIC-conjugated RGD analogue peptides. Hence, [99mTc]Tc-M-7 can be of service to as a new candidate for early detection of αvβ3-positive tumors.

Novel Integrin Αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma.

Integrin Αvβ3-Specific Hydrocyanine for Cooperative Targeting of Glioblastoma with High Sensitivity and Specificity.

Novel Linear Peptides with High Affinity to Αvβ3 Integrin for Precise Tumor Identification.

A New Cyclic RGD Peptide Dimer for Integrin Αvβ3 Imaging.

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

A Novel Integrinαvβ3-Targeted Isodgr Probe for SPECT/CT Imaging of Glioma

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

Imaging integrin αvβ3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake

99Mtc-Hisodgr As a Potential SPECT Probe for Orthotopic Glioma Detection Via Targeting of Integrin Α5β1

Expression Levels of Integrin Αvβ3 Versus Tumor Uptake of 99Mtc-Labeled RGD Peptide

Tumor uptake of the RGD dimeric probe99mTc-G3-2P 4-RGD2 is correlated with integrin αv/β 3 expressed on both tumor cells and neovasculature

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

Specific detection of integrin αvβ3 by light-up bioprobe with aggregation-induced emission characteristics.

In Vivo and in Vitro Studies of 99Tcm-3P-rgd2 Targeting Integrin Αvβ3 in Lung Cancer

Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.

Radiosynthesis and evaluation of 188 Re-c(RGDyK)-His as a novel radiotherapeutic agent for integrin α v β 3 targeting tumour